Ascendia

25 Year BadgeDrug Development & Delivery Celebrates 25 Years!

For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!

  MARKET NEWS

Gilead to Acquire PepStar's Oral Inflammation Drug Program in $1.275B Deal
AAPS PharmSci 360 Spotlights AI and Adaptive Approaches to Drug Development
AstraZeneca Reports Survival Benefit for Experimental ADC in Advanced Stomach Cancer Trial
OpenAI Acquires Orchestra Bio to Connect AI Research With Drug Development Workflows
Menarini Secures Worldwide Rights to Georgiamune's Experimental Oral Immunotherapy in Deal Worth Up to $1.1B
TFS HealthScience Repositions Its CRO Offering Around Clinical Trial Continuity and Therapeutic Expertise
Lilly Invests $5B in Virginia Facility for Advanced Cancer Drug Manufacturing
Former OpenAI Exec Launches Warp Sciences With $215M to Automate Drug Discovery
AI Proteins, Astellas Strike Deal to Develop Computationally Designed Therapeutics
Zylidac Bio and Prolific Machines Team Up to Advance Light-Controlled Biologics Manufacturing
LGM Pharma Expands Analytical Testing Portfolio With Sannova Analytical Acquisition
Recipharm Adds Sterile Semi-Solid Manufacturing Capacity at Portuguese Site

  EXPERT CONTENT & RESOURCES

Adare

 

Industry Education: Credence MedSystems - Insights on Solving Injectable Drug Delivery Challenges

Industry Education: Credence MedSystems - Insights on Solving Injectable Drug Delivery Challenges

As injectable therapies evolve, so do the challenges of delivering them. Credence MedSystems has launched the Industry Education home on our website where we share practical perspectives on important topics in injectable drug delivery, including larger-volume prefilled syringes, precision intravitreal dosing, dual chamber delivery and other emerging drug delivery challenges.

The New Consumer Health Landscape: High Growth, High Expectations

The New Consumer Health Landscape: High Growth, High Expectations

Over the past few years, several major pharmaceutical companies have carved out or spun off their consumer healthcare (CHC) divisions, creating standalone organizations with the scale and scientific heritage of pharma but the commercial ambitions of fast-moving consumer brands. High-profile examples include Kenvue from Johnson & Johnson, Haleon from GSK and Opella from Sanofi, moves intended to unlock greater focus, agility and capital efficiency in businesses that operate under different market dynamics from prescription pharmaceuticals.

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

Modeling Polymor Interactions to Improve Amorphous Dispersion Design

In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.

  FEATURED EDITORIAL

Gattefosse

  EXPERT INSIGHTS VIDEOS

Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges

Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges

  COMPANY PROFILE

 

Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specialising in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture.

With over 25 years of experience, Upperton excels in rapid product introductions.

Our project delivery is unparalleled and designed specifically to align with the values and innovation of small to mid-sized pharma companies.

Learn More

 

Integrated drug development programs so molecules can become cures, fast

With trusted scientific insight brought to every program, Quotient Sciences is a drug development & manufacturing accelerator helping clients bring molecules to cures, fast.

With drug product development, manufacturing, and clinical testing facilities located in both the US and the UK, Quotient Sciences has worked with customers as a trusted CRDMO partner for over 35 years. Our approach to program design and delivery saves time in getting new therapies to market, without compromising quality and control of the product, data, and processes along the way.

Learn More

  WHITEPAPERS & WEBINARS

UPM
WEBINAR - Revolutionize API formulation with AEROPERL® 300 Pharma – Unlocking solubility challenges

WEBINAR - Revolutionize API formulation with AEROPERL® 300 Pharma – Unlocking solubility challenges

Poor aqueous solubility is a key barrier for a growing share of new drug candidates, limiting their bioavailability and development potential. Evonik’s AEROPERL® 300 Pharma excipient helps formulators improve the solubility and bioavailability of poorly water-soluble APIs. Join presenter Carolina Mathias, Senior Applied Technical Manager at Evonik Smart Effects, on Thursday, November 26 at 9:00 a.m. CET for first-hand formulation guidance.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 4 – Drug Delivery
November 11 – Parenteral Contract Manufacturing
November 18 – Controlled Release
November 25 – Bioavailability

To advertise in a future eNewsletter contact:

John Kiesewetter jkiesewetter@drug-dev.com
Amy Nicklaus anicklaus@drug-dev.com

Submit eNewsletter content:

Cindy Dubin cdubin@drug-dev.com
Ralph Vitaro rvitaro@drug-dev.com